Figure 4.

Biodistribution of ¹⁷⁷Lu-labeled DOTA-exendin-4 and DOTA-MI-exendin-4 in BALB/c nude mice bearing subcutaneous CHL-GLP-1R tumors 15 and 30 min and 4, 24, 48, and 72 h after injection. Tumor uptake (A), kidney uptake (B), and pancreatic uptake (C). Receptor saturation was performed by co-injection of a 100-fold excess of the unlabeled peptide 4 h after injection (dotted bars). Values are expressed as the percentage injected activity per gram of tissue (%IA/g) (n = 4–5 mice per group, error bars SD).